Esperion Therapeutics, Inc. · NASDAQ:ESPR

Esperion Therapeutics — J.P. Morgan Healthcare Conference 2026

6 slides from Esperion Therapeutics's conference presentation, Jan 12, 2026

  1. Slide 1: Executing Today While Building for Tomorrow

    =-SPERION VISION Ea 2040 SSR Executing Today While Building for Tomorrow . 4 J.P. Morgan Healthcare Conference «1 Janta Sheldon Koenig, President and CEC ‘© 2025 Esperion Therapeutics, Inc. All rights reserved.

  2. Slide 2: Forward-looking Statements & Disclosures

    Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization and business development plans, current

  3. Slide 3: Multi-Year Proven Track Record of Execution

    Multi-Year Proven Track Record of Execution —— Consistent U.S. Commercial Execution Global Partner Execution * Delivered strong year-over-year revenue and TRX growth + Japan: Successfully executed the commercial launch + Expanded the product label, significantly broadening the U.S. * Canada: Secured

  4. Slide 4: 2025 | A Pivotal Year; the Strongest in Esperion's History

    2025 | A Pivotal Year; the Strongest in Esperion’s History ail FY 2025 PRELIMINARY U.S. NET PRODUCT SALES. $156M — $160M +35% to 38% Y/Y growth TOTAL PRELIMINARY REVENUE $400M — $408M +20% to 23% Y/Y +55% to 59% excluding one-time milestones _ R RETAIL PRESCRIPTION EQUIVALENTS Y/Y +34% = PRELIMINARY

  5. Slide 5: Year in Review

    Year in Review Highlights of 2025 U.S. Commercial Growth PRELIMINARY U.S. NET PRODUCT SALES OF $156M to $160M Market Exclusivity FOUR ANDA SETTLEMENTS, INCLUDING DRREDDY'S Balance Sheet Progress $55M OF DEBT REPAID Pipeline Advancement TRIPLE-COMBINATION PROGRAM, PSC (ESP- 2001), RENAL DISEASE Globa

  6. Slide 6: FY 2026 Operating Expense Guidance

    FY 2026 Operating Expense Guidance FY 2026 Re Dee $40 - 50M + Reflects continued investment in U.S. commercial execution + Supports advancement of pipeline programs, including ESP-2001 and triple combination program FY 2026 SG&A Guidance $170 -195 M $21 0-245M + Maintains focus on disciplined spend

Esperion Therapeutics — J.P. Morgan Healthcare Conference 2026 on 6ix